利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

294 条记录 (耗时 0.042 秒)

    3-Substituted quinuclidines and their use
    73.
    发明申请
    3-Substituted quinuclidines and their use 审中-公开
    3-取代的奎宁和它们的用途

    公开(公告)号：US20080132704A1

    公开(公告)日：2008-06-05

    申请号：US12004022

    申请日：2007-12-20

    申请人： Dan Peters ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Philip K. Ahring ,  Tino Dyhring Jorgensen

    发明人： Dan Peters ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Philip K. Ahring ,  Tino Dyhring Jorgensen

    IPC分类号： C07D453/02

    CPC分类号： C07D453/02

    摘要： This invention relates to novel 3-substituted quinuclidine derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters.Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及新的3-取代的奎宁环衍生物，其被发现是烟碱乙酰胆碱受体的胆碱能配体和单胺受体和转运蛋白的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。

    Isatine derivatives with neurotrophic activity
    74.
    发明授权
    Isatine derivatives with neurotrophic activity 失效
    伊丹替尼衍生物具有神经营养活性

    公开(公告)号：US07282511B2

    公开(公告)日：2007-10-16

    申请号：US10169415

    申请日：2001-01-23

    申请人： Mette Gronborg ,  Dan Peters ,  Arne Moller

    发明人： Mette Gronborg ,  Dan Peters ,  Arne Moller

    IPC分类号： C09B5/00 ,  C07D209/56 ,  A01N43/64 ,  A61K31/41

    CPC分类号： C07D471/04 ,  C07D209/60 ,  C07D487/04

    摘要： The present invention relates to novel isatin derivatives, pharmaceutical compositions comprising the isatin derivatives of the invention, methods of preparing the isatin derivatives of the invention, their use in the treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons, and methods of treatment of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons.

    摘要翻译： 本发明涉及新颖的靛红衍生物，包含本发明靛红衍生物的药物组合物，制备本发明靛红衍生物的方法，它们在治疗神经变性疾病中的用途以及用于再生或预防损伤和损伤的神经元变性 ，以及治疗神经变性疾病和再生或预防损伤和损伤神经元变性的方法。

    Potassium channel blocking agents
    77.
    发明授权
    Potassium channel blocking agents 失效
    钾通道阻断剂

    公开(公告)号：US06380180B1

    公开(公告)日：2002-04-30

    申请号：US09750345

    申请日：2000-12-29

    申请人： Bo Skaaning Jensen ,  Søren Peter Olesen ,  Lene Teuber ,  Dan Peters ,  Dorte Strøbaek

    发明人： Bo Skaaning Jensen ,  Søren Peter Olesen ,  Lene Teuber ,  Dan Peters ,  Dorte Strøbaek

    IPC分类号： A61K31395

    CPC分类号： C07D235/24 ,  C07C279/18 ,  C07D219/08 ,  C07D235/20 ,  C07D235/30 ,  C07D239/42 ,  C07D255/04 ,  C07D403/10 ,  C07D417/04 ,  C07D417/12

    摘要： This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

    摘要翻译： 本发明涉及新型钾通道阻断剂及其在制备药物组合物中的用途。本发明还涉及可用于治疗或缓解与钾通道活性相关的疾病或病症的药物组合物，特别是哮喘， 囊性纤维化，慢性阻塞性肺疾病和鼻漏，惊厥，血管痉挛，冠状动脉痉挛，肾脏疾病，多囊肾病，膀胱痉挛，尿失禁，膀胱流出阻塞，肠易激综合征，肠胃功能障碍，分泌性腹泻，局部缺血，脑缺血 缺血性心脏病，心绞痛，冠心病，创伤性脑损伤，精神病，焦虑，抑郁，痴呆，记忆和注意力缺陷，阿尔茨海默病，痛经，发作性睡眠，雷诺病，间歇性跛行，Sjorgren综合征，偏头痛，心律失常，高血压 阿本森 ce癫痫发作，肌强直性肌营养不良，口干燥症，II型糖尿病，高胰岛素血症，早产，秃发，癌症和免疫抑制。

    Universal container seal
    79.
    发明授权
    Universal container seal 有权
    通用集装箱密封

    公开(公告)号：US09457939B1

    公开(公告)日：2016-10-04

    申请号：US14629255

    申请日：2015-02-23

    申请人： Dan Peters

    发明人： Dan Peters

    IPC分类号： B65D41/02

    CPC分类号： B65D41/023 ,  B65D43/022 ,  B65D51/12 ,  B65D81/245 ,  B65D2543/00037 ,  B65D2543/00092 ,  B65D2543/00194 ,  B65D2543/00203 ,  B65D2543/00296 ,  B65D2543/0049 ,  B65D2543/00546 ,  B65D2543/00851

    摘要： A universal container seal for sealing a container opening includes a resilient body having a top surface and a bottom surface. The body is further configured in a geometric plan form and having a width significantly greater than a thickness, the thickness being greater at a center of the resilient body than at a periphery of the resilient body. At least one gripping portion extends from the top surface of the body. A central portion of the bottom surface of the resilient body is concave. The concave central portion can be in vertical registration with one or more gripping portions.

    摘要翻译： 用于密封容器开口的通用容器密封件包括具有顶表面和底表面的弹性体。 主体进一步构造成几何平面形式并且具有明显大于厚度的宽度，该厚度在弹性体的中心处大于在弹性体的周边处的厚度。 至少一个夹持部分从主体的顶表面延伸。 弹性体的底面的中心部分是凹形的。 凹形中心部分可以与一个或多个夹持部分垂直对准。